This week's news flow around Chemours centers on a wave of securities class action lawsuits and law firm reminders, with multiple firms citing a December 7, 2026 deadline for lead plaintiff status. The underlying allegations concern overstated demand for Opteon products and a lowered full-year 2026 adjusted EBITDA guidance, tied to a Class Period running from February 20, 2026 through August 4, 2026.
Chemours shares closed at $13.39, down 1.6%, sitting below both the 50-day average of $14.96 and the 200-day average of $18.41, with the 50-day below the 200-day. The stock's one-month return is -10.9%, its three-month return is -28.1%, and its six-month return is -41.9%, though the one-year return stands at -2.5%. The GekkoIndex reads 66.9, placing it in the Accumulation zone, and the price sits 5.3% below Gekko Fair Value of $14.14.
Chemours next reports earnings on 5 November 2026, 24 days away, falling inside a typical 20-trading-day holding window. The last quarter saw an EPS of $0.42 against a $0.43 estimate, with a -14.7% reaction, and average absolute reactions have run 9.5%. Over the last 90 days, there have been 4 insider purchases totaling $398,560. Seasonally, the next 20 trading days have averaged +2.6% over 5 years, rising in 3 of them. Analyst consensus target stands at $18.33 across 10 firms, with 5 rating it buy and 5 hold.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Chemours scores 4 supportive, 0 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive0 mixed2 headwinds
Below 50 and 200-day
Close $13.39 is below the 50-day ($14.96) and 200-day ($18.41) averages, and the 50-day is below the 200-day.
See the chart66.9, Accumulation
Reading 66.9 is in the Accumulation zone.
See the GekkoIndex5.3% below
Price is 5.3% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 90 days: 4 open-market insider purchases.
See smart moneyReports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings+2.6% on average
From this point in the calendar, the next 20 trading days averaged +2.6% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Chemours closed at $13.39 on Oct 12, 2026, −2.5% over the past year, inside a 52-week range of $10.44 to $28.67.
Use the left and right arrow keys to read daily values.
Put CC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Chemours makes performance chemicals used across a wide range of industrial and consumer applications, with sales spanning North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. Its product lines include refrigerants and thermal management solutions sold as Freon and Opteon, TiO2 white pigment marketed under the Ti-Pure name for coatings, plastics, and packaging, and specialty materials such as Teflon, Viton, Krytox, and Nafion used in electronics, semiconductors, transportation, energy, and medical fields.
The company is structured around three segments: Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials, each tied to a distinct brand portfolio. Chemours reaches customers through a mix of direct sales, indirect channels, resellers, third-party agents, and distributors, serving industries from building materials and packaging to oil and gas and digital communications.
The company was incorporated in 2014 and is based in Wilmington, Delaware. Its shares are listed on the NYSE under the ticker CC.
Chemours’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 66.9, in the Accumulation zone, up 0.6 points over five sessions.
Up 0.6 points over five sessions.
Reading for Oct 12, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 52 | +4.8% | +4.3% | ||
| Accumulation (current zone) | 294 | −0.6% | −1.9% | ||
| Neutral | 303 | −0.5% | −1.4% | ||
| Distribution | 32 | −1.5% | −0.2% | ||
| Selling | 1 | Too few readings yet | |||
Average CC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Chemours trades 5.3% below Gekko Fair Value of $14.14, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Chemours shares are worth, recalculated every trading day.
$14.14
Gekko Fair Value, Oct 9, 2026
5.3% Undervalued
At the end of Aug 2026 the price was 3.1% above the estimate.
Insiders filed 4 open-market purchases in Chemours worth $399K, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
$399Kin 4 open-market purchases
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 13 | Denise Dignam Chief Executive Officer | Purchase | $51K |
| Aug 11 | Mary B Cranston Director | Purchase | $95K |
| Aug 11 | Alister Cowan Director | Purchase | $203K |
| Aug 10 | Shane Hostetter Chief Financial Officer | Purchase | $50K |
From Form 4 filings, dated to when each was filed.
No trades in CC were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Chemours has been buying back its own shares.
From company filings.
1of the funds Gekko tracks holds CC.
Chemours reports on Nov 5, 2026 (24 days away), and beat the EPS estimate in 3 of its last 8 reports.
Nov 5, 2026
24 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | $0.42 est $0.43 | $1.59B est $1.65B | −14.7% |
| May 5, 2026 | $0.05 est $0.20 | $1.38B est $1.40B | −13.0% |
| Feb 19, 2026 | $0.05 est $0.02 | $1.33B est $1.33B | −19.4% |
| Nov 6, 2025 | $0.20 est $0.24 | $1.50B est $1.33B | +3.8% |
| Aug 5, 2025 | $0.58 est $0.46 | $1.62B est $1.54B | −1.7% |
| May 6, 2025 | $0.13 est $0.19 | $1.37B est $1.35B | −9.9% |
| Feb 18, 2025 | $0.11 est $0.16 | $1.39B est $1.38B | +2.0% |
| Nov 4, 2024 | $0.40 est $0.28 | $1.50B est $1.35B | +11.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Chemours is $18.33, +36.9% from the last close, from 10 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 10 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | Barclays | $16 | +19.5% |
| Oct 5 | BMO Capital | $18 | +34.4% |
| Oct 5 | UBS | $16 | +19.5% |
| Sep 30 | Mizuho Securities | $18 | +34.4% |
| Sep 23 | Mizuho Securities | $20 | +49.4% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Oct 10, Chemours averaged +2.6% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.6% | 4 of 5 |
| Next 10 trading days | −0.4% | 2 of 5 |
| Next 15 trading days | −2.1% | 2 of 5 |
| Next 20 trading days | +2.6% | 3 of 5 |
| Next 30 trading days | +1.5% | 2 of 5 |
For scale, CC’s typical 20-trading-day move in either direction is about 10.1%.
Chemours’s market cap is $2.01B and revenue of $5.80B over the last twelve months.
Coverage of Chemours this week reads negative: 3 positive, 3 neutral and 12 negative headlines.
Chemours’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LINLinde | Neutral | 0.3% below |
| ECLEcolab | Neutral | 9.4% above |
| APDAir Products and Chemicals | Accumulation | 9.5% below |
| DOWDow | Accumulation | 33.5% below |
| LYBLyondellBasell Industries | Accumulation | 10.6% below |
| ALBAlbemarle | Accumulation | 29.6% below |
A peer links to its own page where one exists.
Chemours’s market cap is $2.01B at the Oct 12, 2026 close of $13.39, with 150.5M shares outstanding.
The consensus analyst 12-month price target for Chemours is $18.33, +36.9% from the last close. Of the 10 firms that rated the stock in the last 90 days, 5 rate it a buy, 5 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Chemours is undervalued: the Oct 12, 2026 close of $13.39 is 5.3% below Gekko Fair Value of $14.14. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Chemours is expected to report on Nov 5, 2026 (24 days away). Analysts expect earnings of $0.27 per share on revenue of $1.53B. Chemours beat the earnings estimate in 3 of its last 8 reports, moving 9.5% on average across the report.
Chemours’s 52-week high is $28.67 and its 52-week low is $10.44; it closed at $13.39 on Oct 12, 2026, −2.5% over the past year. Over the last five years the shares peaked at $44.95 on Jun 6, 2022.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and seasonality) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.